X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs ABBOTT INDIA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD ABBOTT INDIA MERCK LTD/
ABBOTT INDIA
 
P/E (TTM) x 27.0 38.2 70.7% View Chart
P/BV x 3.0 9.5 31.7% View Chart
Dividend Yield % 0.9 0.7 133.0%  

Financials

 MERCK LTD   ABBOTT INDIA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
ABBOTT INDIA
Mar-16
MERCK LTD/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,0606,015 17.6%   
Low Rs6233,707 16.8%   
Sales per share (Unadj.) Rs632.41,236.9 51.1%  
Earnings per share (Unadj.) Rs45.7122.2 37.4%  
Cash flow per share (Unadj.) Rs62.3129.0 48.3%  
Dividends per share (Unadj.) Rs11.0035.00 31.4%  
Dividend yield (eoy) %1.30.7 181.5%  
Book value per share (Unadj.) Rs388.8521.2 74.6%  
Shares outstanding (eoy) m16.6021.25 78.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.9 33.9%   
Avg P/E ratio x18.439.8 46.3%  
P/CF ratio (eoy) x13.537.7 35.8%  
Price / Book Value ratio x2.29.3 23.2%  
Dividend payout %24.128.6 84.0%   
Avg Mkt Cap Rs m13,969103,296 13.5%   
No. of employees `0001.63.0 53.6%   
Total wages/salary Rs m1,4873,370 44.1%   
Avg. sales/employee Rs Th6,631.98,891.8 74.6%   
Avg. wages/employee Rs Th939.21,140.0 82.4%   
Avg. net profit/employee Rs Th479.4878.3 54.6%   
INCOME DATA
Net Sales Rs m10,49826,284 39.9%  
Other income Rs m242504 48.1%   
Total revenues Rs m10,74126,789 40.1%   
Gross profit Rs m1,1353,665 31.0%  
Depreciation Rs m276144 190.8%   
Interest Rs m08 0.0%   
Profit before tax Rs m1,1024,017 27.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3431,421 24.2%   
Profit after tax Rs m7592,596 29.2%  
Gross profit margin %10.813.9 77.5%  
Effective tax rate %31.135.4 88.1%   
Net profit margin %7.29.9 73.2%  
BALANCE SHEET DATA
Current assets Rs m6,41014,446 44.4%   
Current liabilities Rs m8,8284,725 186.9%   
Net working cap to sales %-23.037.0 -62.3%  
Current ratio x0.73.1 23.7%  
Inventory Days Days5851 112.2%  
Debtors Days Days3820 196.3%  
Net fixed assets Rs m1,4061,113 126.4%   
Share capital Rs m166213 78.1%   
"Free" reserves Rs m6,28610,808 58.2%   
Net worth Rs m6,45511,076 58.3%   
Long term debt Rs m00-   
Total assets Rs m8,82816,241 54.4%  
Interest coverage xNM497.0-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.6 73.5%   
Return on assets %8.616.0 53.6%  
Return on equity %11.823.4 50.2%  
Return on capital %17.136.3 47.0%  
Exports to sales %8.30.6 1,347.0%   
Imports to sales %21.012.6 166.5%   
Exports (fob) Rs m869162 538.0%   
Imports (cif) Rs m2,2093,322 66.5%   
Fx inflow Rs m959268 357.8%   
Fx outflow Rs m2,6123,927 66.5%   
Net fx Rs m-1,653-3,659 45.2%   
CASH FLOW
From Operations Rs m1,0702,514 42.6%  
From Investments Rs m-750-800 93.8%  
From Financial Activity Rs m-150-803 18.7%  
Net Cashflow Rs m171912 18.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 7.9 230.4%  
FIIs % 1.0 0.1 1,000.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.1 170.2%  
Shareholders   28,591 18,270 156.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   AUROBINDO PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Nov 20, 2017 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS